Katrina Zlataric
Psychiatric/Mental Health · Barnhart, MONPI 1407918386
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 565 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 565 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$679
- Otsuka America Pharmaceutical, Inc.$610
- Neurocrine Biosciences, Inc.$528
- plus $2K from 20 others
What the payments were for
- Food & beverage$7,93999%
- Education$1131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 91 | $1,357 |
| AbbVie | 140 | $1,348 |
| Alkermes, Inc. | 50 | $1,158 |
| Johnson & Johnson | 62 | $679 |
| Otsuka America Pharmaceutical, Inc. | 34 | $610 |
| Neurocrine Biosciences, Inc. | 40 | $528 |
| Axsome Therapeutics, Inc. | 18 | $382 |
| Vanda Pharmaceuticals Inc. | 17 | $351 |
| Teva Pharmaceuticals USA, Inc. | 22 | $298 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $259 |
| Sunovion Pharmaceuticals Inc. | 17 | $180 |
| Orexo US, Inc. | 8 | $176 |
| E.r. Squibb & Sons, L.L.C. | 21 | $158 |
| Almatica Pharma LLC | 8 | $156 |
| Lundbeck LLC | 5 | $94 |
| Noven Therapeutics, LLC | 4 | $56 |
| Adlon Therapeutics L.p. | 3 | $42 |
| Indivior Inc. | 2 | $41 |
| Tris Pharma Inc | 2 | $41 |
| Merck | 2 | $28 |
| Bioxcel Therapeutics, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Corium, LLC | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| TMS Neurohealth Centers Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$438
- LYBALVI$400
- VRAYLAR$125
- ARISTADA INITIO$109
How this compares
$8,052 in reported general payments places this provider in the 90th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 45 | $77,251 |
| RexultiBrexpiprazole | 42 | $71,235 |
| Invega SustennaPaliperidone Palmitate | 12 | $47,594 |
| AristadaAripiprazole Lauroxil | 11 | $33,435 |
| VraylarCariprazine Hcl | 21 | $31,409 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $12,579 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,426 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 33 | $7,676 |
| Aripiprazole | 100 | $5,830 |
| BelsomraSuvorexant | 11 | $4,808 |
| Olanzapine | 158 | $4,007 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 16 | $3,308 |
| Quetiapine Fumarate | 155 | $3,037 |
| Clonazepam | 278 | $2,655 |
| Memantine Hcl | 100 | $2,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,357 | $77,25145 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $610 | $71,23542 claims |
| Johnson & JohnsonInvega Sustenna | $679 | $47,59412 claims |
| Alkermes, Inc.Aristada | $1,158 | $33,43511 claims |
| AbbVieVraylar, Synthroid | $1,348 | $32,00034 claims |
| Axsome Therapeutics, Inc.Auvelity | $382 | $12,57912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $259 | $11,42623 claims |
| MerckBelsomra | $28 | $4,80811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Barnhart
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
- Jeffery DavisCreve Coeur$24K
- Kelsey KingsboroughMexico$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.